Transgenic mouse models of corneal neovascularization: New perspectives for angiogenesis research

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 11, 2014, Pages 7637-7651

  Kather, Jakob Nikolas ^a   Kroll, Jens ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Angiogenesis; Animal model; Cornea; Neovascularization; Transgenic mice

Indexed keywords

ACTIN DEPOLYMERIZING FACTOR; AGANIRSEN; ANGIOPOIETIN 1; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; JUNCTIONAL ADHESION MOLECULE A; LARGAZOLE; MATRIX METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; STEROID; TC14012; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR FOXC1; TRANSCRIPTION FACTOR PAX6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; BIOLOGICAL MARKER; RNA;

ANGIOGENESIS; ANGIOGENESIS ASSAY; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CORNEA INJURY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; CORNEAL POCKET ASSAY; DRUG EFFICACY; DRUG SAFETY; GENE OVEREXPRESSION; HUMAN; IN VIVO STUDY; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW (TOPIC); TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; CORNEA; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; MICE; MICE, TRANSGENIC; RNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84924873012     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15430     Document Type: Article

References (131)

1. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932–936.
2. Kather JN, Kroll J. Rho guanine exchange factors in blood vessels: fine-tuners of angiogenesis and vascular function. Exp Cell Res. 2013;319:1289–1297.
3. Bock F, Maruyama K, Regenfuss B, et al. Novel anti(lymph)-angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res. 2013;34:89–124.
4. Bachmann B, Taylor RS, Cursiefen C. The association between corneal NV and visual acuity: a systematic review. Acta Ophthalmol. 2013;91:12–19.
5. Ellenberg D, Azar DT, Hallak JA, et al. Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res. 2010;29:208–248.
6. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascular-ization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology. 2010;117:1300–1305.
7. Cursiefen C, Schlotzer-Schrehardt U, Kuchle M, et al. Lymphatic vessels in vascularized human corneas: immuno-histochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci. 2002;43:2127–2135.
8. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264–302.
9. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascu-larization. Curr Opin Ophthalmol. 2001;12:242–249.
10. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993–997.
11. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A. 2006;103: 11405–11410.
12. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature. 2001;414:550–554.
13. Cursiefen C, Maruyama K, Bock F, et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med. 2011;208:1083–1092.
14. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med. 2009;15:1023–1030.
15. Seo S, Singh HP, Lacal PM, et al. Forkhead box transcription factor FoxC1 preserves corneal transparency by regulating vascular growth. Proc Natl Acad Sci U S A. 2012;109:2015–2020.
16. Ferrari G, Hajrasouliha AR, Sadrai Z, Ueno H, Chauhan SK, Dana R. Nerves and neovessels inhibit each other in the cornea. Invest Ophthalmol Vis Sci. 2013;54:813–820.
17. Ksander BR, Kolovou PE, Wilson BJ, et al. ABCB5 is a limbal stem cell gene required for corneal development and repair. Nature. 2014;511:353–357.
18. Ahmad S. Concise review: limbal stem cell deficiency, dysfunction, and distress. Stem Cells Transl Med. 2012;1: 110–115.
19. Ouyang H, Xue Y, Lin Y, et al. WNT7A and PAX6 define corneal epithelium homeostasis and pathogenesis. Nature. 2014;511:358–361.
20. Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57:415–429.
21. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003;9:604–613.
22. Tarallo V, Bogdanovich S, Hirano Y, et al. Inhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer. Invest Ophthalmol Vis Sci. 2012;53:7989–7996.
23. Morisada T, Oike Y, Yamada Y, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood. 2005;105: 4649–4656.
24. Kather JN, Friedrich J, Woik N, et al. Angiopoietin-1 is regulated by miR-204 and contributes to corneal neovascu-larization in KLEIP-deficient mice. Invest Ophthalmol Vis Sci. 2014;55:4295–4303.
25. Ambati BK, Joussen AM, Kuziel WA, Adamis AP, Ambati J. Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea. 2003;22:465–467.
26. Dana R. Comparison of topical interleukin-1 vs tumor necrosis factor-alpha blockade with corticosteroid therapy on murine corneal inflammation, neovascularization, and transplant survival (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2007;105:330–343.
27. Wallace GR, John Curnow S, Wloka K, Salmon M, Murray PI. The role of chemokines and their receptors in ocular disease. Prog Retin Eye Res. 2004;23:435–448.
28. Chung ES, Saban DR, Chauhan SK, Dana R. Regulation of blood vessel versus lymphatic vessel growth in the cornea. Invest Ophthalmol Vis Sci. 2009;50:1613–1618.
29. Chang LK, Garcia-Cardena G, Farnebo F, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A. 2004;101:11658–11663.
30. Hajrasouliha AR, Sadrai Z, Chauhan SK, Dana R. b-FGF induces corneal blood and lymphatic vessel growth in a spatially distinct pattern. Cornea. 2012;31:804–809.
31. Yuen D, Pytowski B, Chen L. Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory lymphangiogenesis in early and middle stages. Invest Ophthalmol Vis Sci. 2011;52: 2593–2597.
32. Chung ES, Chauhan SK, Jin Y, et al. Contribution of macrophages to angiogenesis induced by vascular endothe-lial growth factor receptor-3-specific ligands. Am J Pathol. 2009;175:1984–1992.
33. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113:1040–1050.
34. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005;115:2363–2372.
35. Wacker A, Gerhardt H. Endothelial development taking shape. Curr Opin Cell Biol. 2011;23:676–685.
36. Chen Q, Jiang L, Li C, et al. Haemodynamics-driven developmental pruning of brain vasculature in zebrafish. PLoS Biol. 2012;10:e1001374.
37. Cheng C, Haasdijk R, Tempel D, et al. Endothelial cell-specific FGD5 involvement in vascular pruning defines neovessel fate in mice. Circulation. 2012;125:3142–3158.
38. Korn C, Scholz B, Hu J, et al. Endothelial cell-derived non-canonical Wnt ligands control vascular pruning in angiogen-esis. Development. 2014;141:1757–1766.
39. Bucher F, Bi Y, Gehlsen U, Hos D, Cursiefen C, Bock F. Regression of mature lymphatic vessels in the cornea by photodynamic therapy. Br J Ophthalmol. 2014;98:391–395.
40. Koenig Y, Bock F, Kruse FE, Stock K, Cursiefen C. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea. 2012;31:887–892.
41. Zhang H, Hu X, Tse J, Tilahun F, Qiu M, Chen L. Spontaneous lymphatic vessel formation and regression in the murine cornea. Invest Ophthalmol Vis Sci. 2011;52:334–338.
42. Kelley PM, Steele MM, Tempero RM. Regressed lymphatic vessels develop during corneal repair. Lab Invest. 2011;91: 1643–1651.
43. Cursiefen C, Viaud E, Bock F, et al. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN Study. Ophthalmology. 2014;121:1683–1692.
44. Gimbrone MA Jr, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst. 1974;52:413–427.
45. Rogers MS, Birsner AE, D’Amato RJ. The mouse cornea micropocket angiogenesis assay. Nat Protoc. 2007;2:2545–2550.
46. Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010;51: 2813–2826.
47. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res. 2010;29:500–519.
48. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171–1180.
49. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angio-poietin-Tie system. Nat Rev Mol Cell Biol. 2009;10:165–177.
50. Koh GY. Orchestral actions of angiopoietin-1 in vascular regeneration. Trends Mol Med. 2013;19:31–39.
51. Oliner JD, Bready J, Nguyen L, et al. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases. Invest Oph-thalmol Vis Sci. 2012;53:2170–2180.
52. Lee J, Park DY, Park do Y, et al. Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage. Invest Ophthalmol Vis Sci. 2014;55:2191–2199.
53. Kanayama S, Nishida K, Yamato M, et al. Analysis of angiogenesis induced by cultured corneal and oral mucosal epithelial cell sheets in vitro. Exp Eye Res. 2007;85:772–781.
54. Singh N, Macnamara E, Rashid S, et al. Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization. Biochem Biophys Res Commun. 2005;332:194–199.
55. Tang Z, Zhang F, Li Y, et al. A mouse model of the cornea pocket assay for angiogenesis study. J Vis Exp. 2011;54: e3077.
56. Lee H, Schlereth SL, Park EY, Emami-Naeini P, Chauhan SK, Dana R. A novel pro-angiogenic function for interferon-gamma-secreting natural killer cells. Invest Ophthalmol Vis Sci. 2014;55:2885–2892.
57. Cao R, Lim S, Ji H, et al. Mouse corneal lymphangiogenesis model. Nat Protoc. 2011;6:817–826.
58. Sun Y, Su L, Wang Z, Xu Y, Xu X. H-RN, a peptide derived from hepatocyte growth factor, inhibits corneal neovascular-ization by inducing endothelial apoptosis and arresting the cell cycle. BMC Cell Biol. 2013;14:8.
59. Rohan RM, Fernandez A, Udagawa T, Yuan J, D’Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB J. 2000;14:871–876.
60. Regenfuss B, Onderka J, Bock F, Hos D, Maruyama K, Cursiefen C. Genetic heterogeneity of lymphangiogenesis in different mouse strains. Am J Pathol. 2010;177:501–510.
61. Nakao S, Maruyama K, Zandi S, et al. Lymphangiogenesis and angiogenesis: concurrence and/or dependence? Studies in inbred mouse strains. FASEB J. 2010;24:504–513.
62. Hahn N, Dietz CT, Kuhl S, Vossmerbaeumer U, Kroll J. KLEIP deficiency in mice causes progressive corneal neovascular dystrophy. Invest Ophthalmol Vis Sci. 2012;53:3260–3268.
63. Giacomini C, Ferrari G, Bignami F, Rama P. Alkali burn versus suture-induced corneal neovascularization in C57BL/6 mice: an overview of two common animal models of corneal neovascularization. Exp Eye Res. 2014;121:1–4.
64. Cade F, Paschalis EI, Regatieri CV, Vavvas DG, Dana R, Dohlman CH. Alkali burn to the eye: protection using TNF-alpha inhibition. Cornea. 2014;33:382–389.
65. Shin YJ, Hyon JY, Choi WS, et al. Chemical injury-induced corneal opacity and neovascularization reduced by rapamy-cin via TGF-beta1/ERK pathways regulation. Invest Ophthal-mol Vis Sci. 2013;54:4452–4458.
66. Ferrari G, Bignami F, Giacomini C, Franchini S, Rama P. Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring. Invest Ophthalmol Vis Sci. 2013;54:1680–1688.
67. Jin Y, Chauhan SK, El Annan J, Sage PT, Sharpe AH, Dana R. A novel function for programmed death ligand-1 regulation of angiogenesis. Am J Pathol. 2011;178:1922–1929.
68. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea. 1998;17:403–409.
69. Sivak JM, Ostriker AC, Woolfenden A, et al. Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization. J Biol Chem. 2011;286:44965–44975.
70. Lin Z, He H, Zhou T, et al. A mouse model of limbal stem cell deficiency induced by topical medication with the preservative benzalkonium chloride. Invest Ophthalmol Vis Sci. 2013; 54:6314–6325.
71. Das P, Pereira JA, Chaklader M, et al. Phenotypic alteration of limbal niche-associated limbal epithelial stem cell deficiency by ultraviolet-B exposure-induced phototoxicity in mice. Biochem Cell Biol. 2013;91:165-175.
72. Mills RA, Coster DJ, Williams KA. Effect of immunosuppression on outcome measures in a model of rat limbal transplantation. Invest Ophthalmol Vis Sci. 2002;43:647-655.
73. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangio-genesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45:2666-2673.
74. Mulik S, Sharma S, Suryawanshi A, et al. Activation of endothelial roundabout receptor 4 reduces the severity of virus-induced keratitis. J Immunol. 2011;186:7195-7204.
75. Xia L, Zhang S, Cao Z, Hu Y, Yang H, Wang D. Interleukin-17 enhanced immunoinflammatory lesions in a mouse model of recurrent herpetic keratitis. Microbes Infect. 2013;15:126-139.
76. Niederkorn JY, Ubelaker JE, Martin JM. Vascularization of corneas of hairless mutant mice. Invest Ophthalmol Vis Sci. 1990;31:948-953.
77. Smith RS, Hawes NL, Kuhlmann SD, et al. Corn1: a mouse model for corneal surface disease and neovascularization. Invest Ophthalmol Vis Sci. 1996;37:397-404.
78. Cursiefen C, Ikeda S, Nishina PM, et al. Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling. Am J Pathol. 2005;166:1367-1377.
79. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and —2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004;45:1117-1124.
80. Haddadin RI, Oh DJ, Kang MH, et al. Thrombospondin-1 (TSP1)-null and TSP2-null mice exhibit lower intraocular pressures. Invest Ophthalmol Vis Sci. 2012;53:6708-6717.
81. Turpie B, Yoshimura T, Gulati A, Rios JD, Dartt DA, Masli S. Sjogren’s syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol. 2009;175:1136-1147.
82. Contreras-Ruiz L, Regenfuss B, Mir FA, Kearns J, Masli S. Conjunctival inflammation in thrombospondin-1 deficient mouse model of Sjogren’s syndrome. PLoS One. 2013;8: e75937.
83. Maruyama K, Nakazawa T, Cursiefen C, et al. The maintenance of lymphatic vessels in the cornea is dependent on the presence of macrophages. Invest Ophthalmol Vis Sci. 2012; 53:3145-3153.
84. Mwaikambo BR, Sennlaub F, Ong H, Chemtob S, Hardy P. Genetic ablation of CD36 induces age-related corneal neovascularization. Cornea. 2008;27:1037-1041.
85. Nakamura T, Hamuro J, Takaishi M, et al. LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis.J Clin Invest.2014;124:385-397.
86. Chatterjee S, Wang Y, Duncan MK, Naik UP. Junctional adhesion molecule-A regulates vascular endothelial growth factor receptor-2 signaling-dependent mouse corneal wound healing. PLoS One. 2013;8:e63674.
87. Cooke VG, Naik MU, Naik UP. Fibroblast growth factor-2 failed to induce angiogenesis in junctional adhesion mole-cule-A-deficient mice. Arterioscler Thromb Vasc Biol. 2006; 26:2005-2011.
88. Davis J, Piatigorsky J. Overexpression of Pax6 in mouse cornea directly alters corneal epithelial cells: changes in immune function, vascularization, and differentiation. Invest Ophthalmol Vis Sci. 2011;52:4158-4168.
89. Ramaesh T, Collinson JM, Ramaesh K, Kaufman MH, West JD, Dhillon B. Corneal abnormalities in Pax6+/- small eye mice mimic human aniridia-related keratopathy. Invest Ophthalmol Vis Sci. 2003;44:1871-1878.
90. Baulmann DC, Ohlmann A, Flugel-Koch C, Goswami S, Cvekl A, Tamm ER. Pax6 heterozygous eyes show defects in chamber angle differentiation that are associated with a wide spectrum of other anterior eye segment abnormalities. Mech Dev. 2002;118:3–17.
91. Nacak TG, Alajati A, Leptien K, et al. The BTB-Kelch protein KLEIP controls endothelial migration and sprouting angio-genesis. Circ Res. 2007;100:1155–1163.
92. Kaminska GM, Niederkorn JY. Spontaneous corneal neovas-cularization in nude mice. Local imbalance between angio-genic and anti-angiogenic factors. Invest Ophthalmol Vis Sci. 1993;34:222–230.
93. Vauclair S, Majo F, Durham AD, Ghyselinck NB, Barrandon Y, Radtke F. Corneal epithelial cell fate is maintained during repair by Notch1 signaling via the regulation of vitamin A metabolism. Dev Cell. 2007;13:242–253.
94. Ikeda S, Cunningham LA, Boggess D, et al. Aberrant actin cytoskeleton leads to accelerated proliferation of corneal epithelial cells in mice deficient for destrin (actin depoly-merizing factor). Hum Mol Genet. 2003;12:1029–1037.
95. Hara T, Ishida H, Raziuddin R, Dorkhom S, Kamijo K, Miki T. Novel kelch-like protein, KLEIP, is involved in actin assembly at cell-cell contact sites of Madin-Darby canine kidney cells. Mol Biol Cell. 2004;15:1172–1184.
96. Kawakami-Schulz SV, Sattler SG, Doebley AL, Ikeda A, Ikeda S. Genetic modification of corneal neovascularization in Dstn (corn1) mice. Mamm Genome. 2013;24:349–357.
97. Kawakami-Schulz SV, Verdoni AM, Sattler SG, Ikeda A, Ikeda S. Differences in corneal phenotypes between destrin mutants are due to allelic difference and modified by genetic background. Mol Vis. 2012;18:606–616.
98. Jin Y, Arita M, Zhang Q, et al. Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest Ophthalmol Vis Sci. 2009;50:4743–4752.
99. Cho YK, Uehara H, Young JR, Archer B, Ambati BK. Effect of glucocorticoid (triamcinolone acetonide) pretreatment in a murine penetrating keratoplasty and suture model. Cornea. 2012;31:1468–1475.
100. Steven P, Bock F, Huttmann G, Cursiefen C. Intravital two-photon microscopy of immune cell dynamics in corneal lymphatic vessels. PLoS One. 2011;6:e26253.
101. Bock F, Onderka J, Hos D, Horn F, Martus P, Cursiefen C. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res. 2008;87:462–470.
102. Blacher S, Detry B, Bruyere F, Foidart JM, Noel A. Additional parameters for the morphometry of angiogenesis and lymphangiogenesis in corneal flat mounts. Exp Eye Res. 2009;89:274–276.
103. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009;127:381–389.
104. Fraz MM, Remagnino P, Hoppe A, et al. Blood vessel segmentation methodologies in retinal images–a survey. Comput Methods Programs Biomed. 2012;108:407–433.
105. Ecoiffier T, Yuen D, Chen L. Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Oph-thalmol Vis Sci. 2010;51:2436–2440.
106. Truong T, Huang E, Yuen D, Chen L. Corneal lymphatic valve formation in relation to lymphangiogenesis. Invest Ophthal-mol Vis Sci. 2014;55:1876–1883.
107. Shi W, Ming C, Liu J, Wang T, Gao H. Features of corneal neovascularization and lymphangiogenesis induced by different etiological factors in mice. Graefes Arch Clin Exp Ophthalmol. 2011;249:55–67.
108. Cursiefen C, Colin J, Dana R, et al. Consensus statement on indications for antiangiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable. Br J Ophthalmol. 2012;96:3–9.
109. Adini I, Ghosh K, Adini A, et al. Melanocyte-secreted fibromodulin promotes an angiogenic microenvironment. J Clin Invest. 2014;124:425–436.
110. Panigrahy D, Kalish BT, Huang S, et al. Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A. 2013;110:13528–13533.
111. Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J. 2013;27:45–50.
112. Lee HK, Chauhan SK, Kay E, Dana R. Flt-1 regulates vascular endothelial cell migration via a protein tyrosine kinase-7-dependent pathway. Blood. 2011;117:5762–5771.
113. Ghanem RC, Han KY, Rojas J, et al. Semaphorin 7A promotes angiogenesis in an experimental corneal neovascularization model. Curr Eye Res. 2011;36:989–996.
114. Zhou H, Jiang S, Chen J, Ren X, Jin J, Su SB. Largazole, an inhibitor of class I histone deacetylases, attenuates inflammatory corneal neovascularization. Eur J Pharmacol. 2014;.
115. Shen M, Yuan F, Jin J, Yuan Y. The effect of TC14012 on alkali burn-induced corneal neovascularization in mice. Ophthalmic Res. 2014;52:17–24.
116. Yuen D, Grimaldo S, Sessa R, et al. Role of angiopoietin-2 in corneal lymphangiogenesis. Invest Ophthalmol Vis Sci. 2014; 55:3320–3327.
117. Chan MF, Li J, Bertrand A, et al. Protective effects of matrix metalloproteinase-12 following corneal injury. J Cell Sci. 2013;126:3948–3960.
118. Toyono T, Usui T, Yokoo S, et al. Angiopoietin-like protein 2 is a potent hemangiogenic and lymphangiogenic factor in corneal inflammation. Invest Ophthalmol Vis Sci. 2013;54: 4278–4285.
119. Yang H, Li X, Ma J, et al. Blockade of the intermediate-conductance Ca(2þ)-activated Kþ channel inhibits the angiogenesis induced by epidermal growth factor in the treatment of corneal alkali burn. Exp Eye Res. 2013;110:76–87.
120. Liu GQ, Lu PR, Li LB, Zhang XG. Inhibited experimental corneal neovascularization by neutralizing anti-SDF-1alpha antibody. Int J Ophthalmol. 2012;5:7–12.
121. Yan ZX, Jiang ZH, Liu NF. Angiopoietin-2 promotes inflammatory lymphangiogenesis and its effect can be blocked by the specific inhibitor L1-10. Am J Physiol Heart Circ Physiol. 2012;302:H215–223.
122. Markowska AI, Jefferies KC, Panjwani N. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem. 2011;286:29913–29921.
123. Hos D, Regenfuss B, Bock F, Onderka J, Cursiefen C. Blockade of insulin receptor substrate-1 inhibits corneal lymphangio-genesis. Invest Ophthalmol Vis Sci. 2011;52:5778–5785.
124. Hos D, Saban DR, Bock F, et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical cortico-steroids. Arch Ophthalmol. 2011;129:445–452.
125. Lin Q, Yang XP, Fang D, et al. High-mobility group box-1 mediates toll-like receptor 4-dependent angiogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1024–1032.
126. Grimaldo S, Yuen D, Ecoiffier T, Chen L. Very late antigen-1 mediates corneal lymphangiogenesis. Invest Ophthalmol Vis Sci. 2011;52:4808–4812.
127. Tang XL, Sun JF, Wang XY, Du LL, Liu P. Blocking neuropilin-2 enhances corneal allograft survival by selectively inhibiting lymphangiogenesis on vascularized beds. Mol Vis. 2010;16: 2354–2361.
128. Koo BH, Coe DM, Dixon LJ, et al. ADAMTS9 is a cell-autonomously acting, antiangiogenic metalloprotease ex-pressed by microvascular endothelial cells. Am J Pathol. 2010;176:1494–1504.
129. Chen Y, Carlson EC, Chen ZY, et al. Conditional deletion of Cited2 results in defective corneal epithelial morphogenesis and maintenance. Dev Biol. 2009;334:243–252.
130. Dou GR, Wang YC, Hu XB, et al. RBP-J, the transcription factor downstream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice. FASEB J. 2008;22:1606–1617.
131. Bellner L, Patil KA, Castellano K, Halilovic A, Dunn MW, Schwartzman ML. Targeted suppression of HO-2 gene expression impairs the innate anti-inflammatory and repair responses of the cornea to injury. Mol Vis. 2011;17:1144–1152.